Aim To investigate total homocysteine (tHcy) serum concentration in patients with probable vascular dementia (VD) and in agematched controls, as well as to determine an association between tHcy serum concentration and cognitive impairment in patients with probable VD. Methods Serum concentration of tHcy was determined by the Fluorescence Polarization Immunoassay on the AxSYM System. Cognitive impairment was tested by the Mini Mental Status Examination (MMSE) score. Body mass index (BMI) was calculated for each subject included in the study. Results Age, systolic, diastolic blood pressure and BMI did not differ significantly between the two groups. Mean serum tHcy concentration in the control group of subjects was 13.35 µmol/L, while in patients with probable VD it was significantly higher, 19.45 µmol/L (p=0.002). A negative but insignificant association between serum tHcy concentration and cognitive impairment in patients with probable VD was found. Conclusion Increased tHcy concentration in patients with probable VD suggests the possible independent role of Hcy in the pathogenesis of VD.
Kalaria R. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease. Acta Neuropathol. 2016. p. 659–85.
2.
Ganguly P, Alam S. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015. p. 6.
3.
Schalinske K, Smazal A. Homocysteine imbalance: a pathological metabolic marker. Adv Nutr. 2012. p. 755–62.
4.
Ashjazadeh N, Fathi M, Shariat A. Evaluation of homocysteine level as a risk factor among patients with ischemic stroke and its subtypes. Iran J Med Sci. 2013. p. 233–9.
5.
Spence J, Howard V, Chambless L, Malinow M, Pettigrew L, Stampler M, et al. Vitamin Intervention for Stroke Prevention (VISP) trial: Rationale and design. Neuroepidemiology. 2001. p. 16–25.
6.
Tehlivets O. Homocysteine as a risk ractor for atherosclerosis: Is its conversion to S-Adenosyl-Lhomocysteine the key to deregulated lipid metabolism. J Lipids. 2011. p. 702853.
7.
Dolan H, Crain B, Troncoso J, Resnick S, Zonderman A, Obrien R. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore longitudinal study of aging cohort. Ann Neurol. 2010. p. 231–40.
8.
Wang B, Zhong Y, Yan H, Cui L. Meta-analysis of plasma homocysteine content and cognitive function in elderly patients with Alzheimer’s disease and vascular dementia. Int J Clin Exp Med. 2014. p. 5118–23.
9.
Cai C, Van Halm-Lutterodt X, Zhen N, Huang J, Xu X, Chen Y, et al. Association of MTHFR, SLC19A1 genetic polymorphism, serum folate, vitamin B12 and Hcy status with cognitive functions in Chinese adults. Nutrients. 2016. p. 10.
10.
Román G, Tatemichi K, Erkinjuntti T, Cummings J, Masdeu J, Garcia J, et al. Vascular dementia: diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. Neurology. 1993. p. 250–60.
11.
Folstein M, Folstein S, Mchugh P. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975. p. 189–98.
12.
Loncarević N, Sulić M, Alajbegović E, Kucukalić A, A. The neurologist role in diagnostics and therapy of the Alzheimer’s disease. Med Arh. 2005. p. 6–9.
13.
Pernet P, Lasnier E, Vaubourdolle M. Evaluation of the AxSYM homocysteine assay and comparison with the IMx homocysteine assay. Clin Chem. 2000. p. 1440–1.
14.
Khedr E, Hamed S, El-Shereef H, Shawky O, Mohamed K, Awad E, et al. Cognitive impairment after cerebrovascular stroke: Relationship to vascular risk factors. Neuropsychiatr Dis Treat. 2009. p. 103–16.
15.
Lepara O, Alajbegovic A, Zaciragic A, Nakas-Icindic E, Valjevac A, Lepara D, et al. Elevated serum homocysteine level is not associated with serum C-reactive protein in patients with probable Alzheimer’s disease. J Neural Transm. 2009. p. 1651–6.
16.
Folin M, Baiguera S, Gallucci M, Conconi M, Liddo D, Zanardo R, et al. A cross-sectional study of homocysteine-, NO-levels, and CT-findings in Alzheimer dementia, vascular dementia and controls. Biogerontology. 2005. p. 255–60.
17.
Seshadri S. Homocysteine and the risk of dementia. Clin Chem. 2012. p. 1059–60.
18.
Moretti R, Caruso P, Ben D, Conti M, Gazzin C, Tiribelli S, et al. Vitamin D, homocysteine, and folate in subcortical vascular dementia and Alzheimer dementia. Front Aging Neurosci. 2017. p. 169.
19.
Luchsinger J, Tang M, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology. 2004. p. 1972–6.
20.
Haan M, Miller J, Aiello A, Whitmer R, Jagust W, Mungas D, et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr. 2007. p. 511–7.
21.
Lehotský J, Tothová B, Kovalská M, Dobrota D, Beňová A, Kalenská D, et al. Role of Homocysteine in the Ischemic Stroke and Development of Ischemic Tolerance. Front Neurosci. 2016. p. 538.
22.
Kloppenborg R, Nederkoorn P, Van Der Graaf Y, Geerlings M. Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR study. Atherosclerosis. 2011. p. 461–6.
23.
Wang Y, He Y, Jiang W, Du B, Jin. Correlation between plasma level of homocysteine and cerebral large-artery atherosclerosis. Zhonghua Nei Ke Za Zhi. 2006. p. 744–7.
24.
Nilson K, Gustafson L, Huktberg B. Relation between plasma homocysteine and Alzheimer’s Disease. Dement Geriatr Cogn Disord. 2002. p. 7–12.
25.
Nivo homocisteina u serumu pacijenata s mogućom vaskularnom demencijom Salem Alajbegović 1 , Orhan Lepara 2* , Almira Hadžović-Džuvo Almira 2. Alma Mutevelić-Turković.
26.
Predstavništvo u Sarajevu; Bosna i Herzegovina SAŽETAK Cilj Ispitati koncentraciju ukupnog homocisteina (tHcy) u serumu pacijenata s mogućom vaskularnom demencijom (VD) i kod ispitanika kontrolne grupe, te utvditi povezanost između nivoa tHcy i kognitivnog oštećenja kod pacijenata s mogućom VD-om.
27.
Indeks tjelesne mase (ITM) izračunat je za svakog ispitanika uključenog u studiju.
28.
Utvrđena je negativna, ali ne signifikantna povezanost između serumske koncentracije tHcy i kognitivnog oštećenja kod pacijenata s mogućim VD-om.
29.
Zaključak Povećan nivo tHcy kod pacijenata s mogućim VD-om sugeriše na moguću nezavisnu ulogu Hcy u patogenezi VD-a. Ključne riječi: neurotoksičnost, kognitivno oštećenje, minimentalni status.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
